Literature DB >> 27313682

HSP90 expression and its association with wighteone metabolite response in HER2-positive breast cancer cells.

Zhong-Wei Cao1, Qian Zeng2, Hai-Jiang Pei1, Li-Dong Ren1, Hai-Zhen Bai1, Ri-Na Na1.   

Abstract

It is well known that heat shock protein 90 (HSP90) overexpression is correlated with poor prognosis and chemo-resistance in human malignant cancers. At the same time, wighteone, or 6-prenyl-5,7,4'-trihydroxyisoflavone, a major isoflavone component of the ornamental tall tree Erythrina suberosa, has been demonstrated to exhibit a potent anti-proliferative effect on human leukemia HL-60 cancer cell lines. In this study, the effects of wighteone on the proliferation of HER2-positive breast cancer cells were investigated, and the action mechanism was explored. MCF-7 HER2-positive breast cancer cells were treated with various concentrations of wighteone. The growth inhibitory rate of the cells was calculated by MTT assay, apoptosis was detected by flow cytometry, and the expression level of HSP90 was assessed by western blot analysis. The addition of wighteone at concentrations ranging from 1-10 g/ml in the medium for 48 h had a marked inhibition on the proliferation of HER2-positive cancer cell lines. The growth inhibitory rates with 0.5, 2 or 8 mM wighteone were significantly higher compared with the control group. Apoptosis in the wighteone-treated cells was also significantly higher compared with the control group. The expression level of HSP90 in the wighteone group was significantly lower than that in the control group. Our findings demonstrated that wighteone effectively inhibited the proliferation of HER2-positive cancer cell lines, and this is considered to be the result of downregulating HSP90 receptor and downstream signaling.

Entities:  

Keywords:  apoptosis; breast cancer; metabolite; protein expression; wighteone

Year:  2016        PMID: 27313682      PMCID: PMC4888280          DOI: 10.3892/ol.2016.4488

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

Review 1.  Development and application of Hsp90 inhibitors.

Authors:  David B Solit; Gabriela Chiosis
Journal:  Drug Discov Today       Date:  2007-11-26       Impact factor: 7.851

2.  Induction of apoptosis in human promyelocytic leukemia HL60 cells by an extract from Erythrina suberosa stem bark.

Authors:  Satyam Kumar Agrawal; Madhunika Agrawal; Parduman Raj Sharma; Bishan Datt Gupta; Saroj Arora; Ajit Kumar Saxena
Journal:  Nutr Cancer       Date:  2011-06-28       Impact factor: 2.900

3.  Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.

Authors:  Peter M Smith-Jones; David Solit; Farzana Afroze; Neal Rosen; Steven M Larson
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

4.  High HSP90 expression is associated with decreased survival in breast cancer.

Authors:  Elah Pick; Yuval Kluger; Jennifer M Giltnane; Christopher Moeder; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

5.  The anticancer potential of flavonoids isolated from the stem bark of Erythrina suberosa through induction of apoptosis and inhibition of STAT signaling pathway in human leukemia HL-60 cells.

Authors:  Sunil Kumar; Anup Singh Pathania; A K Saxena; R A Vishwakarma; Asif Ali; Shashi Bhushan
Journal:  Chem Biol Interact       Date:  2013-07-09       Impact factor: 5.192

Review 6.  Hsp90: an emerging target for breast cancer therapy.

Authors:  Jason Beliakoff; Luke Whitesell
Journal:  Anticancer Drugs       Date:  2004-08       Impact factor: 2.248

7.  On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.

Authors:  Anna Orlova; Helena Wållberg; Sharon Stone-Elander; Vladimir Tolmachev
Journal:  J Nucl Med       Date:  2009-02-17       Impact factor: 10.057

Review 8.  Discovery and development of heat shock protein 90 inhibitors.

Authors:  Tony Taldone; Weilin Sun; Gabriela Chiosis
Journal:  Bioorg Med Chem       Date:  2008-11-06       Impact factor: 3.641

9.  Heat shock protein as molecular targets for breast cancer therapeutics.

Authors:  Lee Su Kim; Jun Ho Kim
Journal:  J Breast Cancer       Date:  2011-09-29       Impact factor: 3.588

10.  Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target.

Authors:  Mariëlle I Gallegos Ruiz; Karijn Floor; Paul Roepman; José A Rodriguez; Gerrit A Meijer; Wolter J Mooi; Ewa Jassem; Jacek Niklinski; Thomas Muley; Nico van Zandwijk; Egbert F Smit; Kristin Beebe; Len Neckers; Bauke Ylstra; Giuseppe Giaccone
Journal:  PLoS One       Date:  2008-03-05       Impact factor: 3.240

View more
  5 in total

1.  Isoflavonoid-Antibiotic Thin Films Fabricated by MAPLE with Improved Resistance to Microbial Colonization.

Authors:  Valentina Grumezescu; Irina Negut; Rodica Cristescu; Alexandru Mihai Grumezescu; Alina Maria Holban; Florin Iordache; Mariana Carmen Chifiriuc; Roger J Narayan; Douglas B Chrisey
Journal:  Molecules       Date:  2021-06-14       Impact factor: 4.411

2.  Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells.

Authors:  Hyung Joon Kim; Mi Kyung Gong; Cheol Yong Yoon; Jaeku Kang; Mijin Yun; Nam Hoon Cho; Sun Young Rha; Young Deuk Choi
Journal:  Yonsei Med J       Date:  2020-07       Impact factor: 2.759

3.  Aryl Hydrocarbon Receptor Activation Produces Heat Shock Protein 90 and 70 Overexpression, Prostaglandin E2/Wnt/β-Catenin Signaling Disruption, and Cell Proliferation in MCF-7 and MDA-MB-231 Cells after 24 h and 14 Days of Chlorpyrifos Treatment.

Authors:  Paula Moyano; José Manuel Garcia; Jimena García; Adela Pelayo; Pilar Muñoz-Calero; María Teresa Frejo; Andrea Flores; Javier Del Pino
Journal:  Chem Res Toxicol       Date:  2021-08-23       Impact factor: 3.973

4.  Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer.

Authors:  Peiyuan Sun; Yana Qu; Yuna Wang; Jing Wang; Xuanjun Wang; Jun Sheng
Journal:  J Cancer       Date:  2021-05-05       Impact factor: 4.207

5.  The Cytotoxic and Antimigratory Activity of Brazilin-Doxorubicin on MCF-7/HER2 Cells.

Authors:  Riris Istighfari Jenie; Sri Handayani; Ratna Asmah Susidarti; Linar Zalinar Udin; Edy Meiyanto
Journal:  Adv Pharm Bull       Date:  2018-08-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.